Literature DB >> 17660385

[3H]A-778317 [1-((R)-5-tert-butyl-indan-1-yl)-3-isoquinolin-5-yl-urea]: a novel, stereoselective, high-affinity antagonist is a useful radioligand for the human transient receptor potential vanilloid-1 (TRPV1) receptor.

Bruce R Bianchi1, Rachid El Kouhen, Torben R Neelands, Chih-Hung Lee, Arthur Gomtsyan, Shirish N Raja, Sriajan N Vaidyanathan, Bruce Surber, Heath A McDonald, Carol S Surowy, Connie R Faltynek, Robert B Moreland, Michael F Jarvis, Pamela S Puttfarcken.   

Abstract

1-((R)-5-tert-butyl-indan-1-yl)-3-isoquinolin-5-yl-urea (A-778317) is a novel, stereoselective, competitive antagonist that potently blocks transient receptor potential vanilloid-1 (TRPV1) receptor-mediated changes in intracellular calcium concentrations (pIC50 = 8.31 +/- 0.13). The (S)-stereoisomer, 1-((S)-5-tert-butyl-indan-1-yl)-3-isoquinolin-5-yl-urea (A-778316), is 6.8-fold less potent (pIC50 = 7.47 +/- 0.07). A-778317 also potently blocks capsaicin and acid activation of native rat TRPV1 receptors in dorsal root ganglion neurons. A-778317 was tritiated ([3H]A-778317; 29.3 Ci/mmol) and used to study recombinant human TRPV1 (hTRPV1) receptors expressed in Chinese ovary cells (CHO) cells. [3H]A-778317 labeled a single class of binding sites in hTRPV1-expressing CHO cell membranes with high affinity (KD = 3.4 nM; Bmax = 4.0 pmol/mg protein). Specific binding of 2 nM [3H]A-778317 to hTRPV1-expressing CHO cell membranes was reversible. The rank-order potency of TRPV1 receptor antagonists to inhibit binding of 2 nM [3H]A-778317 correlated well with their functional potencies in blocking TRPV1 receptor activation. The present data demonstrate that A-778317 blocks polymodal activation of the TRPV1 receptor by binding to a single high-affinity binding site and that [3H]A-778317 possesses favorable binding properties to facilitate further studies of hTRPV1 receptor pharmacology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17660385     DOI: 10.1124/jpet.107.124305

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

Review 1.  TRPV1: on the road to pain relief.

Authors:  Andrés Jara-Oseguera; Sidney A Simon; Tamara Rosenbaum
Journal:  Curr Mol Pharmacol       Date:  2008-11       Impact factor: 3.339

Review 2.  Calcium signals that determine vascular resistance.

Authors:  Matteo Ottolini; Kwangseok Hong; Swapnil K Sonkusare
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2019-03-18

3.  The analgesic effect and mechanism of the combination of sodium ferulate and oxymatrine.

Authors:  Hanqing Liu; Yan Sun; Yan Gao; Fangfang Chen; MingBo Xu; Zhifeng Liu
Journal:  Neurochem Res       Date:  2010-06-03       Impact factor: 3.996

4.  Extra-endothelial TRPV1 channels participate in alcohol and caffeine actions on cerebral artery diameter.

Authors:  Kelsey C North; Jennifer Chang; Anna N Bukiya; Alex M Dopico
Journal:  Alcohol       Date:  2018-04-26       Impact factor: 2.405

5.  Novel Radiolabeled Vanilloid with Enhanced Specificity for Human Transient Receptor Potential Vanilloid 1 (TRPV1).

Authors:  Larry V Pearce; Jihyae Ann; Aeran Jung; Shivaji A Thorat; Brienna K A Herold; Amelework D Habtemichael; Peter M Blumberg; Jeewoo Lee
Journal:  J Med Chem       Date:  2017-09-21       Impact factor: 7.446

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.